Study of the Effects of Probiotics on Gastrointestinal Symptoms in Patients with Scleroderma

Study of the Effects of a Probiotic product on Gastrointestinal Symptoms in Patients with Scleroderma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250805066768N1

Enrollment

Registered

2025-09-19

Start date

2025-09-23

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scleroderma. Systemic sclerosis [scleroderma]

Interventions

Intervention 1: Intervention group: Receiving one capsule of BioZenD probiotic supplement daily. Intervention 2: Control group: Receiving one capsule of placebo daily.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Over 18 years old Patient consent to participate in the study Having scleroderma Having digestive symptoms

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
UCLA SCTC GIT Questionnaire Score. Timepoint: Before starting the intervention and after taking probiotic for 2 months. Method of measurement: UCLA SCTC GIT Questionnaire.	—

Secondary

Measure	Time frame
Quality of Life with SF-36 Questionnaire Score. Timepoint: Before starting the intervention and after taking probiotic for 2 months. Method of measurement: SF-36 Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdiye Abiyarghamsari

Shahid Beheshti University of Medical Sciences

ghamsari@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026